Mesenchymal stromal cells for organ transplantation
- 1 February 2014
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Current Opinion in Organ Transplantation
- Vol. 19 (1), 41-46
- https://doi.org/10.1097/mot.0000000000000036
Abstract
PURPOSE OF THE REVIEW: In this review, recent findings on the effects of tissue and donor origin, culturing conditions and preconditioning regimens on the therapeutic effect of mesenchymal stem cells (MSC) in organ transplantation are discussed and the importance of understanding the characteristics of MSC for developing efficient therapy is stressed. RECENT FINDINGS: MSC research in organ transplantation is currently moving from safety-feasibility studies to efficacy studies and finding the optimal MSC for therapy is therefore highly relevant. Although sharing basic properties, there are subtle differences between MSC from different tissue sources that may affect their efficacy. Furthermore, the use of MSC from diseased organ recipients, donor or third party may affect their therapeutic effect. The importance of these differences in MSC properties may however be overshadowed by the impact of culture conditions on MSC. Culture conditions dramatically change the characteristics of MSC, and this situation can be exploited by exposing MSC to preconditioning treatment to bring about the desired properties in MSC. As MSC appear to be short-lived after infusion, the specific characteristics of MSC are mostly relevant for short-term interactions between MSC and host cells, which will subsequently take over the effects of MSC. The multiple effects of MSC are by no means unique, but the full spectrum of the effects in combination with their easy isolation and expansion make MSC a suitable cell type for therapy. SUMMARY: Tissue source, donor source and culture conditions affect the phenotypical and functional properties of MSC. The efficacy of MSC therapy will therefore depend on the source and manipulation of MSCKeywords
This publication has 48 references indexed in Scilit:
- Mesenchymal stem cells attenuate ischemic acute kidney injury by inducing regulatory T cells through splenocyte interactionsKidney International, 2013
- Pre-conditioned mesenchymal stem cells ameliorate renal ischemic injury in rats by augmented survival and engraftmentJournal of Translational Medicine, 2012
- Mesenchymal stem cells are short-lived and do not migrate beyond the lungs after intravenous infusionFrontiers in Immunology, 2012
- Resident Tissue-Specific Mesenchymal Progenitor Cells Contribute to Fibrogenesis in Human Lung AllograftsThe American Journal of Pathology, 2011
- Adipose-Derived Mesenchymal Stem Cell Protects Kidneys against Ischemia-Reperfusion Injury through Suppressing Oxidative Stress and Inflammatory ReactionJournal of Translational Medicine, 2011
- Fresh and cryopreserved, uncultured adipose tissue-derived stem and regenerative cells ameliorate ischemia–reperfusion-induced acute kidney injuryNephrology Dialysis Transplantation, 2010
- Homing of stem cells to sites of inflammatory brain injury after intracerebral and intravenous administration: a longitudinal imaging studyStem Cell Research & Therapy, 2010
- Mouse Bone Marrow-Derived Mesenchymal Stromal Cells Turn Activated Macrophages into a Regulatory-Like ProfilePLOS ONE, 2010
- Evidence for tissue-resident mesenchymal stem cells in human adult lung from studies of transplanted allograftsJCI Insight, 2007
- Comparative Analysis of Mesenchymal Stem Cells from Bone Marrow, Umbilical Cord Blood, or Adipose TissueThe International Journal of Cell Cloning, 2006